ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,262.08
1.38%
Dow Jones
44,296.51
0.97%
Gold vs US Dollar
2,715.28
0.00%
Brent Oil
74.65
0.00%
Bitcoin
98,368.28
0.60%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Synaptogenix Inc (SNPX)

  7. Synaptogenix Inc (SNPX) News

Synaptogenix (SNPX)

Synaptogenix Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SNPX
DateTimeSourceHeadlineSymbolCompany
12/11/202422:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNPXSynaptogenix Inc
07/11/202413:54Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SNPXSynaptogenix Inc
05/11/202411:01Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SNPXSynaptogenix Inc
28/10/202420:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SNPXSynaptogenix Inc
22/10/202404:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SNPXSynaptogenix Inc
10/10/202421:11Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SNPXSynaptogenix Inc
04/10/202420:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
23/09/202421:04Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SNPXSynaptogenix Inc
13/09/202420:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
11/09/202413:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
11/09/202413:00PR Newswire (US)Synaptogenix Announces $5.0 Million FinancingNASDAQ:SNPXSynaptogenix Inc
09/09/202421:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
14/08/202420:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNPXSynaptogenix Inc
18/07/202413:00PR Newswire (US)Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord InjuryNASDAQ:SNPXSynaptogenix Inc
26/06/202413:00PR Newswire (US)Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple SclerosisNASDAQ:SNPXSynaptogenix Inc
15/05/202421:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SNPXSynaptogenix Inc
07/05/202413:00PR Newswire (US)Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug DiscoveryNASDAQ:SNPXSynaptogenix Inc
24/04/202413:15PR Newswire (US)Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued ListingNASDAQ:SNPXSynaptogenix Inc
09/04/202413:15PR Newswire (US)Synaptogenix Increases Stake in Innovative Psilocybin Drug Discovery Company through its Partnership with Cannasoul AnalyticsNASDAQ:SNPXSynaptogenix Inc
03/04/202412:00PR Newswire (US)Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq ListingNASDAQ:SNPXSynaptogenix Inc
06/02/202415:16Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SNPXSynaptogenix Inc
21/12/202322:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
19/12/202314:00PR Newswire (US)Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative DisordersNASDAQ:SNPXSynaptogenix Inc
06/12/202314:00PR Newswire (US)Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sNASDAQ:SNPXSynaptogenix Inc
14/11/202322:05Edgar (US Regulatory)Form ARS - Annual Report to Security HoldersNASDAQ:SNPXSynaptogenix Inc
13/11/202322:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SNPXSynaptogenix Inc
06/11/202322:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SNPXSynaptogenix Inc
03/11/202321:00Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SNPXSynaptogenix Inc
02/11/202313:00PR Newswire (US)Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of TechnologyNASDAQ:SNPXSynaptogenix Inc
26/09/202313:00PR Newswire (US)Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's DiseaseNASDAQ:SNPXSynaptogenix Inc
 Showing the most relevant articles for your search:NASDAQ:SNPX

Your Recent History

BIT
UB8HS1
Unicredit Bank
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    BLACK FRIDAY

    ADVFN

    Celebrating 25 years Est 1999-2024

    Save up to 60%* for Silver

    1 year 40%, 2 years 50% and *3 years 60%

    *Across 3 years £903.96 only 361.58